StockData
Krystal Biotech, Inc. logo

Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)

Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –

Krystal Biotech operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Krystal Biotech's operating cash flow for the twelve months ending Jun 30, 2026 was $272.34M, up 39.4% year over year. For fiscal 2025 it was $200.87M, up 62.7% from the year before. The highest annual figure on record is $200.87M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$200.87M+62.7%
FY2024Dec 31, 2024$123.42M–
FY2023Dec 31, 2023-$88.80M–
FY2022Dec 31, 2022-$100.57M–
FY2021Dec 31, 2021-$47.94M–
FY2020Dec 31, 2020-$26.08M–
FY2019Dec 31, 2019-$18.69M–
FY2018Dec 31, 2018-$9.45M–
FY2017Dec 31, 2017-$3.89M–
FY2016Dec 31, 2016-$1.31M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$74.79M+41.8%
Q1 FY2026Mar 31, 2026$80.38M+159.6%
Q4 FY2025Dec 31, 2025$77.51M+46.7%
Q3 FY2025Sep 30, 2025$39.66M-32.6%
Q2 FY2025Jun 30, 2025$52.73M–
Q1 FY2025Mar 31, 2025$30.97M+94.9%
Q4 FY2024Dec 31, 2024$52.84M–
Q3 FY2024Sep 30, 2024$58.86M–
Q2 FY2024Jun 30, 2024-$4.17M–
Q1 FY2024Mar 31, 2024$15.89M–
Q4 FY2023Dec 31, 2023-$7.23M–
Q3 FY2023Sep 30, 2023-$21.23M–
Q2 FY2023Jun 30, 2023-$34.19M–
Q1 FY2023Mar 31, 2023-$26.16M–
Q4 FY2022Dec 31, 2022-$22.33M–
Q3 FY2022Sep 30, 2022-$19.69M–
Q2 FY2022Jun 30, 2022-$43.06M–
Q1 FY2022Mar 31, 2022-$15.49M–
Q4 FY2021Dec 31, 2021-$20.90M–
Q3 FY2021Sep 30, 2021-$7.26M–
Q2 FY2021Jun 30, 2021-$10.13M–
Q1 FY2021Mar 31, 2021-$9.65M–
Q4 FY2020Dec 31, 2020-$8.02M–
Q3 FY2020Sep 30, 2020-$6.78M–
Q2 FY2020Jun 30, 2020-$5.05M–
Q1 FY2020Mar 31, 2020-$6.23M–
Q4 FY2019Dec 31, 2019-$7.00M–
Q3 FY2019Sep 30, 2019-$4.27M–
Q2 FY2019Jun 30, 2019-$4.21M–
Q1 FY2019Mar 31, 2019-$3.22M–
Q4 FY2018Dec 31, 2018-$3.52M–
Q3 FY2018Sep 30, 2018-$1.94M–
Q2 FY2018Jun 30, 2018-$1.62M–
Q1 FY2018Mar 31, 2018-$2.37M–
Q4 FY2017Dec 31, 2017-$2.13M–
Q3 FY2017Sep 30, 2017-$1.10M–
Q2 FY2017Jun 30, 2017-$408.00K–
Q1 FY2017Mar 31, 2017-$257.00K–
Q4 FY2016Dec 31, 2016-$861.00K–

More Krystal Biotech figures

See a number that looks wrong?